Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Frequently asked questions
What sector does 09R (09R) operate in?
09R belongs to the Other sector and operates in the Biotechnology industry.
What is 09R (09R) current stock price?
As of the latest data, 09R stock price is €1.41, with a previous close of €1.41.
What is 09R (09R) current market capitalization?
09R market cap is approximately 6.24 million.
What is 09R (09R) Earnings Per Share (EPS)?
The trailing EPS is -€8.76.
Does 09R (09R) pay dividends?
No. 09R does not pay a dividend.
When is 09R (09R) next earnings report?
09R is expected to release its next earnings report on September 30, 2026.
What is 09R (09R) beta (volatility) score?
09R has a beta of 2.990, indicating very high volatility compared to the market.
